Panacea Biotec: No Shares Dematerialized in March 2026; Total 6.11 Crore Dematerialized
Panacea Biotec reported no share dematerialization in March 2026. As of March 31, 2026, a total of 6,11,04,526 shares were dematerialized, with 5,35,51,635 through NSDL and 75,52,891 through CDSL.
This is a standard compliance filing that provides information on the dematerialization of shares, which is a routine process and does not have a significant impact on the company's operations or stock.
The announcement is a routine regulatory filing regarding share dematerialization status and does not contain information that positively or negatively impacts the company's financial performance or outlook.
Panacea Biotec Limited has submitted its share dematerialization status report for the month of March 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The company informed the stock exchanges that no shares were dematerialized during the month of March 2026.
As of March 31, 2026, the total number of shares dematerialized stood at 6,11,04,526. This comprises 5,35,51,635 shares with NSDL and 75,52,891 shares with CDSL. A certificate from the company's Registrar and Share Transfer Agent, Skyline Financial Services Pvt. Ltd., confirming these details, has also been enclosed.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.